지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Background: Lung cancer is increasing exponentially as the population ages. To conquer lung cancer, early diagnosis, developing new treatments, and combining multidisciplinary treatment modalities are essential.
Current Concepts: Since the national lung cancer screening program for high-risk individuals using low-dose chest computed tomography has launched, the rate of early diagnosis of lung cancer is expected to increase.
The development of immune checkpoint inhibitors and target agents is paying off in terms of producing new anticancer drugs. Immune checkpoint inhibitors are administered in combination with existing treatment modalities in various clinical situations, such as for not only patients with metastatic lung cancer but also for those with resectable lung cancer and with surgically unresectable locally advanced disease. These trials dramatically improved survival outcomes. The development of targeted anticancer drugs is also advancing at a rapid pace.
The survival rate of patients with lung cancer who have specific gene mutations has greatly improved when targeted anticancer drugs are administered alone or in combination with conventional therapies.
Discussion and Conclusion: Early diagnosis of lung cancer and the development of new treatment modalities are greatly improving the prognosis of patients with lung cancer. Attempts to combine conventional and new treatment modalities should continue. It is necessary to discuss changing medical policies for long-term survivors, which will inevitably increase.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Epidemiology of Lung Cancer in Korea: Recent Trends
Tuberculosis and Respiratory Diseases
2016 .01
-
Higher Age Puts Lung Cancer Patients at Risk for Not Receiving Anti-cancer Treatment
Cancer Research and Treatment
2019 .01
-
국가 폐암 검진
대한내과학회지
2020 .04
-
비소세포폐암의 새로운 표적치료
대한의사협회지
2023 .03
-
폐암의 바이오마커와 진단도구
대한의사협회지
2021 .01
-
Risk Factors for Lung Cancer Mortality in a Referral Center
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Clinical Usefulness of Human Epididymis Protein 4 in Lung Cancer
Annals of Laboratory Medicine
2017 .01
-
Gene mutation discovery research of non-smoking lung cancer patients due to indoor radon exposure
대한직업환경의학회지
2016 .03
-
Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Indicators and Qualitative Assessment of Lung Cancer Management by Health Insurance Review and Assessment Service (HIRA) of Korea in 2015
Tuberculosis and Respiratory Diseases
2018 .01
-
Study on Theoretical Models of Regional Humanity Lung Cancer Hazards Assessment
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Lung Cancer in a Rural Area of China: Rapid Rise in Incidence and Poor Improvement in Survival
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Interstitial Lung Disease and Lung Cancer Development: A 5-Year Nationwide Population-Based Study
Cancer Research and Treatment
2018 .01
-
Risk of Coronavirus Disease Incidence, Severe Presentation, and Mortality in Patients with Lung Cancer
Cancer Research and Treatment
2021 .01
-
폐암 환자의 치료 및 관리에서 한의학적 치료의 역할
대한암한의학회지
2015 .01
-
Clinical Characteristics and Prognostic Factors of Lung Cancer in Korea: A Pilot Study of Data from the Korean Nationwide Lung Cancer Registry
Tuberculosis and Respiratory Diseases
2019 .01
-
Chemotherapy for Lung Cancer in the Era of Personalized Medicine
Tuberculosis and Respiratory Diseases
2019 .01
-
Clinical Efficacy and Possible Applications of Genomics in Lung Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Immunotherapy for Non-small-cell Lung Cancer : Current Status and Future Obstacles
Immune Network
2017 .12
-
The Development of the Korean Lung Cancer Registry (KALC-R)
Tuberculosis and Respiratory Diseases
2019 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0